Alcoholic hepatitis is inflammation of the liver, which is caused due to heavy consumption of alcohol. It can lead to serious conditions such as fluid build-up in the abdomen, confusion, and bleeding in the esophagus.
Looking for more information on this market? Request a free sample report
There is no effective treatment for severe alcoholic hepatitis. Hence, researchers are focusing on developing combination therapies, as they are more effective. For instance, at the University of Massachusetts Medical School, researchers are studying a combination therapy with Kineret, Trental, and zinc sulfate. The combination showed short and long-term survival benefits in patients with severe alcoholic hepatitis.
Phase II clinical trial is being conducted by Gilead Sciences to evaluate the safety and tolerability ofselonsertib (GS-4997) in combination with prednisolone in the patients. An antibiotic combined with a corticosteroid is being evaluated by researchers by targeting the group of patients at a high risk of death due to alcoholic hepatitis. Such developments of combination therapies to treat severe alcoholic hepatitis are expected to drive the growth of the global alcoholic hepatitis treatment market at a CAGR of 5.85% during the forecast period.
Browse Full Report – http://bit.ly/2OCF2rT